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Abstract
The genetic basis for rheumatoid arthritis (RA) is likely to be extremely complex. Even the
role of MHC genes remains to be fully defined, and may involve interactive genetic effects.
The difficulty of precisely defining the clinical phenotype, as well as underlying genetic
heterogeneity, complicates the problem. In addition, stochastic genetic or physiologic events
may contribute to the low penetrance of susceptibility genes. This situation parallels
developing paradigms for other autoimmune disorders, in which many different genes each
appear to contribute a small amount to overall risk for disease, and where severity and
specific phenotypic subtypes are subject to genetic effects. The completion of the human
genome project, along with advances in informatics, will be required to reach a deeper
understanding of RA. It is likely that this will involve an iterative and interactive process
between several different scientific disciplines. 
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Introduction
Now that we are beginning to feel the impact of human
genomic research on biomedical science, those of us who
are attempting to apply the tools of modern genetics to
autoimmune disorders are being forced to confront a
sobering reality – genetically complex disorders really are
complex! This lesson is also being learned by geneticists
working on other polygenic diseases, including psychiatric
and metabolic disorders, and cancer. The heyday of iden-
tifying the molecular basis for diseases caused by one or a
few high-penetrance genes is not yet over, as illustrated
by the recent exciting progress in defining the periodic
fever syndromes [1,2]. However, the future challenges are
largely going to involve understanding the genetic under-
pinnings of common disorders that are generally ‘sporadic’,
in the sense that they do not exhibit a high degree of
familial recurrence. It is likely though that genetics will be
important for understanding these diseases. 
A fundamental feature of mammalian organisms, not to
mention single cells, is that they are very complex. For
cell biologists, biochemists, and even scientists working
with whole organisms, however, clever experiments can
be designed that attempt to control for this complexity,
and enable one to manipulate and examine the effects of
isolated changes in a parameter of interest. When it comes
to the study of genetics and polygenic human disease,
however, the experiments have already been done, and
we must make do with interpreting the results as they
exist in the human population. The task of the researcherArthritis Research    Vol 1 No 1 Gregersen
38
is to define a unifying set of parameters to study (ie care-
fully define the phenotype), and to seek out and interpret
the informative mating experiments that are hidden
within modern populations. This requires a group of skills
that are rarely found in one individual, and this naturally
leads to collaborations among scientists with expertise in
clinical disease definition, disease pathogenesis, and mole-
cular and statistical genetics. The experimental designs
also generally require large sample sizes, and therefore
patients and clinicians must do their part if we are to
succeed in bringing such studies to fruition. Finally, tech-
nology is a major force behind this rapidly moving field,
and has a substantial influence on the kinds of experi-
ments that can be contemplated. This review highlights
some of these current trends as they relate to the problem
of rheumatoid arthritis (RA).
Estimating the size of the genetic component
in rheumatoid arthritis
RA does not aggregate in families with very high fre-
quency. In addition, concordance rates in identical
(monozygotic) twins are relatively low (12–15% see [3,4])
compared with other autoimmune disorders, which gener-
ally have monozygotic twin concordance rates in the range
of 30% [4]. Nevertheless, the prevalence rates of RA in
first-degree relatives of probands with RA are considerably
higher than in the general population as a whole. A com-
parison of disease prevalence rates in populations of indi-
viduals with different degrees of genetic relatedness can
be used to calculate risk ratios, or l. The relative risk to
siblings of affected probands, compared with that in the
general (unrelated) population, is a widely used measure
[5], and is calculated as follows:
Disease prevalence in siblings of affected individuals
ls = 
Disease prevalence in general population
For many of the common autoimmune disorders, ls values
appear to be in the range 10–20, or higher [6]. However, for
RA the true ls is highly uncertain and ranges from a low of
2 to at least 10, although the prevalence in siblings of
affected persons is generally agreed to be in the 2–4%
range [7]. There are at least two reasons for this uncer-
tainty. First, and probably most important, is the fact that
RA is very likely to be a clinical syndrome with a heteroge-
neous etiology. One has only to consider the difficulty of
obtaining meaningful data if the broad category of ‘arthri-
tis’ were used as the defining phenotype for a ls calcula-
tion. In that case, one would lump in
spondyloarthropathies, hemochromatosis and other highly
genetic disorders into the calculation, and the ls value
would be low and misleading. Our inability to define RA
precisely makes it difficult to know whether additional
highly genetic subtypes of ‘rheumatoid arthritis’ exist. The
second problem, related to the first, is the inaccuracy of
defining background prevalence for this disease. A preva-
lence of 0.8–1% is generally cited [8]. Both under-reporting
and over-reporting of ‘true’ prevalence is probably
common, however, because of misdiagnosis, lack of current
disease activity, and again the problem of disease defini-
tion. In addition, severity of disease, which is also likely to
have a genetic component [9,10], is not readily assessed in
large population prevalence surveys.
The description of the human leukocyte antigen (HLA)
associations with RA over two decades ago [11] has been a
major source of support for the hypothesis that genetic
factors are important for susceptibility to RA. The contri-
bution of HLA to the overall genetic risk has been vari-
ously estimated at between 30 and 50% [7]. Depending on
your assumptions regarding the ls, this estimate for the
HLA contribution may be too low or too high. Several
recent studies of HLA haplotype sharing among affected
sibling pairs with RA [12,13] are in excellent agreement,
and indicate that the HLA region contributes a l of about
1.7 to the total ls. If the total ls is as low as 2, this leaves
little room for a major contribution by other genes. On the
other hand, if the ls is 10, the majority of genetic suscepti-
bility must be due to non-HLA genes.
The nongenetic component
Usually a tacit assumption is made that ‘nongenetic’ com-
ponents of disease really refer to environmental factors.
Despite the obvious role of microbial agents in some
forms of inflammatory arthritis, the search for infectious
causes for RA has been frustrating [14]. Other environ-
mental factors, such as body weight, smoking, and blood
transfusion, may make a modest contribution to disease
risk [15]. Similar to genetic associations, a role for these
factors must be confirmed by replicating these findings in
large populations. A second type of ‘nongenetic’ factor
relates to chance events, however, some of which may
occur either early in development, or before the onset of
disease. Clearly, because the concordance rate for
monozygotic twins is relatively low (12–15%), and the
‘environmental’ contributions appear to be modest, it is
reasonable to explore additional explanations for the rela-
tively low penetrance of disease in individuals who are
known to be genetically predisposed (ie unaffected
cotwins from discordant monozygotic twin pairs with RA).
There are at least three broad areas in which stochastic
processes might influence disease penetrance: somatic
genetic events, epigenetic events, and physiologic events
at the biochemical and cellular level.
The importance of chance somatic mutation is a widely
accepted concept in the field of cancer research. The
recent reports of mutations in p53 in synovial tissue are
provocative, and raise the possibility that somatic muta-
tions might also play a role in RA [16]. In addition, the39
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rearrangements of immunoglobulin and T-cell receptors
are examples of normal somatic genetic events that can
generate diversity between genetically identical individu-
als. It must be admitted, however, that the importance of
these somatic genetic mechanisms for differential disease
susceptibility has not been directly demonstrated for RA,
or for any other autoimmune disease.
On the other hand, somatic epigenetic events have clearly
been shown to influence phenotypes other than cancer.
This is well illustrated by the example of X-chromosome
inactivation [17]. In females, a choice regarding which X
chromosome should be inactivated in each cell is made
very early in embryonic life, and not infrequently results
in the preferential utilization of either paternally or mater-
nally derived X-linked genes [18]. This can result in dis-
cordant expression of X-linked phenotypes in identical
twins, due to the epigenetic influence of DNA methyla-
tion and chromosomal structure on gene transcription [19].
Interestingly, such monoallelic expression of genes also
occurs on autosomes, including several cytokine genes
[20,21], as well as other chromosomal regions subject to
genomic imprinting [22]. The degree of random variation
in this process, or other epigenetic phenomena, is largely
unexplored, and might contribute to the discordant
expression of autosomal susceptibility genes that are rele-
vant to autoimmune disease [23]. One interesting variant
of this line of thought is the idea that epigenetic variation
per se might be a risk factor for disease. A hypothesis incor-
porating this idea with respect to X-chromosome inactiva-
tion has been proposed to explain the higher prevalence of
autoimmune disease in women [24]. So far, our data do not
support this hypothesis [25] (Gregersen PK, unpublished
data), but the concept remains an intriguing one.
Finally, chance variation, or an individual’s tendency
toward higher degrees of variation, in normal biochemical
and cellular processes might predispose to dysregulation of
inflammatory processes. For example, the difference
between positive and negative thymic selection of the T-
cell repertoire is currently thought to be a result of rather
small differences in the binding energy of each T-cell
receptor for particular MHC-self peptide combinations
[26]. Indeed, similar small differences in binding affinity
determine agonist versus antagonist responses by periph-
eral T cells. This explains how extremely subtle changes in
either peptide, MHC, or T-cell receptor structure may
have a profound influence on the outcome of T-cell stimu-
lation [26]. There are bound to be numerous aspects of T-
cell receptor–MHC peptide interactions in the thymus that
are subject to chance; it seems highly unlikely that all thy-
mocytes are exposed to all MHC peptide combinations, in
the same density and in the same cellular context. It is rea-
sonable to suppose that there are geographic, circadian, or
other types of variation in the selecting environment for
each thymocyte. Perhaps this variation increases with age,
as the thymus slowly involutes. At some point, thymocytes
that usually would cross the affinity threshold for negative
selection may end up being positively selected, or vice
versa, resulting in a peripheral repertoire with different
tendencies for stimulation by cross-reactive antigens.
Admittedly, this example implies a role for cross-reactive
T-cell recognition in the pathogenesis of RA, a hypothesis
that remains to be proved. Analogous sources of variation,
however, might lead to the chance crossing of thresholds
for cytokine feedback amplification or cell migration into
sites of injury and inflammation. Obviously, this concept
can be also be extended to include variations in the physi-
ologic state of an organism at the time of exposure to envi-
ronmental risk factors. This kind of variability could partly
explain the low penetrance of RA, as reflected in the com-
monly discordant expression of disease among monozy-
gotic twins.
The major histocompatibility complex in
susceptibility to rheumatoid arthritis
Since the late 1980s, a consensus has developed around
susceptibility to RA being due to a closely related set of
polymorphic sequences (the ‘shared epitope’) on several
different DRB1 alleles, especially certain subtypes of the
DR4 and DR1 allelic families [27,28]. It is still unclear
how this set of class II alleles operates to confer suscepti-
bility to RA, however. Popular models invoke selective
peptide presentation of autoantigens [28], biased thymic
selection toward an autoreactive T-cell repertoire [29],
direct effects on antigen processing [30], and a direct role
for the shared epitope itself as a nominal peptide antigen
[31], to name a few. The unifying concept of the shared
epitope has considerable appeal for understanding the
MHC class II associations with RA, but it is clearly an
oversimplification to consider the shared epitope as the
only relevant MHC polymorphism for susceptibility to RA
[32]. There are important haplotypic influences on the
degree of risk conferred by the shared epitope alleles.
Certain shared epitope alleles, such as DRB1*0401, confer
much greater risk than others, such as DRB1*0101 [33]. In
addition, homozygosity for particular combinations of hap-
lotypes, such as DRB1*0401/0404, appear to confer espe-
cially high risk or influence disease severity as well as risk
[10,34,35]. Differences in female versus male risk have
been described for different alleles [36]. Some investiga-
tors have proposed a role for DQ alleles on these haplo-
types [37], although so far no convincing population data
in humans supports this. It must be admitted, however,
that it is very difficult to identify large enough populations
to do the risk comparisons for interactive effects between
DR and DQ, because DR4 and DQ3 alleles are so com-
monly found on the same haplotypes.
Another recent development has been the sequencing of
most of the MHC, and the realization that the ‘central’MHC contains many genes that could be directly involved
in disease risk, or might interact with DRB1 alleles to
modify risk [38]. Tumor necrosis factor (TNF)-a is a par-
ticularly compelling candidate because of the obvious
therapeutic importance of this cytokine. Several recent
reports suggest that polymorphisms in the TNF region
may interact with DR alleles to modify susceptibility to
RA [39,40]. These studies will need to be replicated and
confirmed using large numbers of patients and well
matched control individuals, but they emphasize that our
understanding of the MHC influences on susceptibility to
RA is far from complete.
Identifying susceptibility genes outside of the
major histocompatibility complex
The candidate gene approach
One approach to identifying genetic susceptibility alleles
outside the MHC is to analyze polymorphisms in genes
that can reasonably be implicated in a pathway of patho-
genesis [41]. Obviously, success depends on having a
model of pathogenesis that at the very least involves rele-
vant biochemical pathways, and on selecting the right
genes in these pathways to study. It is highly uncertain
whether either of these prerequisites can be fulfilled by
our current knowledge. Most candidate genes that have
been addressed to date involve immune recognition,
cytokines and their receptors, or genes generally thought
to be involved in inflammation. Of course ‘inflammation’
entails a large number of cellular processes, so that the list
of candidates can get very broad, and could reasonably
extend to a large fraction of the 100000–150000 genes
now thought to reside in the human genome.
An additional problem is that the extent of genetic poly-
morphism is not well defined for many candidate genes of
interest, and many polymorphisms exist in untranslated
regulatory portions of genes, often in the form of single
nucleotide polymorphisms (SNPs) or variable numbers of
tandem repeats. Usually it is unclear whether these SNPs
and variable numbers of tandem repeats have any func-
tional significance, although there are examples where
transcription does appear to correlate with these types of
sequence changes [42,43]. Clearly, the premise underlying
a candidate gene approach dictates that functional changes
should be of most interest. Recent surveys indicate that
SNPs within coding regions are biased towards silent, and
presumably functionally irrelevant, substitutions [44,45].
This is consistent with evolutionary selection against dele-
terious mutations. Nevertheless, functionally irrelevant
polymorphisms may be in linkage disequilibrium with
other sequence differences that do affect function. This
implies that a general screen of SNPs or other types of
polymorphisms within and around a candidate gene can
be a rational approach, regardless of their direct functional
effects. As discussed below, however, there is some
debate concerning this point [46].
Positive associations between RA and a number of candi-
date genes have been reported, and a few have been repli-
cated. Variable results have been reported for the T-cell
receptor loci [47–50]. Among the cytokines (other than
TNF), a recent report of an association with interleukin
(IL)-4 is provocative [51]. Studies of IL-1, IL-1 receptor
antagonist, and IL-10 show only weak or negative associa-
tions [51,52]. IL-10 is of interest because promoter poly-
morphisms in this gene are associated with differences in
levels of transcription [42], and low IL-10 expressing hap-
lotypes may influence the asthma phenotype [53]. Modest
associations (estimated relative risks in the 1.3–2 range)
with cytotoxic T-lymphocyte associated antigen-4 have
been reported in RA [54,55], as well as in type I diabetes
[56,57] and Graves’ disease [57]. Other candidate genes
that do not fall strictly into the immunological category
include corticotrophin releasing hormone [58], glutathione
S-transferase [59], and Nramp1 [60].
Overall, the evidence for associations with most of these
candidates is only suggestive at best. It should be remem-
bered that the sample size requirements are substantial to
detect these kinds of modest associations. For example,
even for an allele that is quite common in the population
(20%), the sample size required to achieve 80% power to
detect a relative risk of 1.3 is 1324 individuals per group.
For detection of relative risks of 1.5, 1.7 or 2.0, the required
sample sizes are 535, 304 and 172 respectively. Many
studies do not achieve these sample sizes. Therefore, major
resources must be put into clinical recruitment if these
observations are to be convincingly demonstrated and con-
firmed. In addition, stratification of patient populations into
groups that carry certain other alleles, such as particular
MHC haplotypes, is likely to be required. This can occa-
sionally reveal evidence of striking interactive effects [56].
Screening the genome
An alternative and complementary approach is to pursue a
genome-wide screening strategy, instead of focusing on
particular candidate genes. This has the advantage of
avoiding any assumptions about the molecular pathways
involved in disease pathogenesis. Currently, the only fea-
sible method of doing this depends on searching for
linkage within multiplex families. A preferred approach
for RA is to utilize affected sibling pairs (ASP) [7], because
this avoids the necessity of defining any family members
as unaffected. (Defining a family member as ‘unaffected’
is particularly difficult for RA, because the age of onset
may be late in life; in addition, an unaffected family
member may well carry susceptibility genes, due to the
low penetrance of RA.) Several major collections of
affected sibling pairs are now being carried out [12,61,62].
The European Consortium for Rheumatoid Arthritis Fam-
ilies published the first genome screen of such families
(total of 308 sibling pairs) and has reported preliminary
evidence for linkage to a number of different chromoso-
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[12]. A second major collection of RA sibling pairs in the
UK is currently being analyzed [62].
In the USA, the North American Rheumatoid Arthritis
Consortium was established in 1997 with the goal of iden-
tifying 1000 affected RA sibling pairs [61]. Over 600 fami-
lies have now been ascertained. A preliminary analysis of
180 affected sibling pairs confirms the estimated lHLA of
1.7 which was reported by the European Consortium for
Rheumatoid Arthritis Families, but fails to confirm
linkage to the region around 3q13 [12,13] (North Ameri-
can Rheumatoid Arthritis Consortium, unpublished obser-
vations). These results demonstrate the utility of ASP for
mapping susceptibility regions such as the MHC, but also
emphasize the importance of having large numbers of
such families in order to detect chromosomal regions con-
taining genes which confer only modest risk. Because of
the relatively lower statistical power of the ASP linkage-
based method compared with association studies [63],
both positive and negative findings on a few hundred
sibling pairs must be viewed with caution.
In order to foster optimal utilization of the North Ameri-
can Rheumatoid Arthritis Consortium collection of data on
RA families, a web site has been established to provide
access for the scientific community. This site
(http://narac.patternrx.com) will go online in November
1999. It contains detailed clinical information on these
families (anonymized and coded to preserve patient confi-
dentiality), including digitized and downloadable hand
radiographs on all affected siblings, joint evaluations using
the joint alignment and mobility score [64], and HLA and
serological data. This site will also be a repository for
genotyping data. There are several levels of access to the
site, and access to gentoyping data and DNA samples will
be available to investigators. The intent is to provide an
information resource that will steadily increase in value as
genetic information accumulates on these families to
permit genotype–phenotype correlations.
Integrating diverse methods and technologies
to identify rheumatoid arthritis susceptibility
genes
While the study of RA families will probably lead to the
identification of one or more regions outside the MHC
that contains susceptibility genes, this method will not
permit the identification of these genes. Linkage by ASP
will at best permit narrowing a region of interest to 5–10
million base pairs. A region of this size contains a large
number of genes. Hopefully most of the genes will be
known by virtue of the completion of the Human Genome
Project. We will then still be faced with a large number of
candidate genes to investigate. In this sense, linkage
mapping using affected sibling pairs can be thought of as a
method of hypothesis generation, by focusing attention on
a more limited, but still large, set of candidate genes. In
this case, the rationale for the hypothesis rests on gene
location, rather than on involvement in a pathway of
pathogenesis.
Therefore, the end game for gene identification is going
to involve the evaluation of candidates. This will likely be
an iterative process involving knowledge of gene location,
pattern of expression, evidence for involvement in path-
ways of pathogenesis, and discovery of functionally rele-
vant allelic variants. Any techniques or advances that
contribute to these factors will be important components
of successful gene identification.
Recently, SNPs have received a lot of attention as a power-
ful tool for genetic analysis [65]. These polymorphisms may
be present in 0.05–0.15% of the human genome, implying
the existence of 2–6 million such SNPs. Several recent
analyses [44,45] suggested that the majority of these changes
are silent within coding regions [44,45]. SNPs in promoter
and regulatory regions may affect gene expression [42,66].
Furthermore, even in the absence of function, a dense col-
lection of SNPs in a candidate gene or region of interest may
be very useful for genetic mapping by linkage disequilib-
rium, although this may not be the case for all regions of the
genome [46,67]. At present, however, the data on SNPs is
limited, and SNP databases are only just beginning to be
organized (see http://www.ncbi.nlm.nih.gov/SNP/). The
development of such resources is critical to allow investiga-
tors to pursue the efficient analysis of candidate genes for
RA, or any other disease. In addition, reasonably large
sample sizes are going to be required to pursue this approach
to gene identification [68]. Finally, the best methods for
achieving high throughput SNP typing are still being
worked out [69,70].
Advances in microarray technology will also permit more
intelligent and directed selection of candidate genes [71].
In the next few years, it is likely that massive parallel
analysis of gene expression will become accessible to indi-
vidual investigators. This may permit the identification of
characteristic changes in patterns of gene expression in
specific cells, tissues and patient populations. Clearly,
comprehensive data on patterns of gene expression in
rheumatoid synovial cells, monocyte or dendritic cell
subsets may lead to reasonable new candidate genes. A
database of SNPs in these genes would then permit a
rapid analysis of patient populations for evidence of asso-
ciation with SNP haplotypes.
Information technologies and analytic tools are another
important component for candidate gene evaluation.
Internet access to the clinical and genetic data, as well as
physical access to DNA, from well defined patient popula-
tions will likely be increasingly valuable to individual
investigators who are pursuing a gene of interest. This is
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ment may only be apparent in subsets of patients who
have particular phenotypic and genotypic characteristics.
This relates to the analytic problem of gene–gene interac-
tion effects in disease susceptibility, it may be that the
effects of some loci are dependent on particular alleles at a
second locus, a phenomenon termed epistasis [72]. Thus,
in analyzing affected sibling pairs, stratifying the popula-
tion by sharing at HLA may reveal stronger evidence for
linkage at a second non-HLA locus. These types of
genetic interactions have clearly been shown in murine
models of autoimmunity [73], and evidence for this phe-
nomenon is beginning to emerge in human studies [74]. If
such epistatic interactions involve multiple loci, it
becomes computationally challenging to examine all the
different possible combinations. The continuing develop-
ment of new analytic methods by statistical geneticists
will clearly be important for future progress in this area.
Rheumatoid arthritis genetic susceptibility in
the larger context of human autoimmune
disease
A recent analysis by Becker et al [75] ignited renewed
interest in the question of whether there are common
genes underlying multiple forms of autoimmunity. A
review of both human and rodent mapping studies indi-
cated that chromosomal regions linked to autoimmunity
are not randomly distributed across the genome, but rather
appear to cluster in at least 18 regions [75]. Indeed, even
within the human MHC, it has been known for many
years that certain haplotypes, such as A1-B8-DR3 are asso-
ciated with different autoimmune phenotypes [38]. A
more recent example may be the polymorphisms in cyto-
toxic T-lymphocyte associated antigen-4, which appear to
associate with RA, type I diabetes and autoimmune
thyroid disease [54–57].
Another means of assessing this genetic overlap is to
examine the aggregation of different autoimmune disor-
ders within families. Perhaps the most compelling evi-
dence involves the aggregation of type I diabetes and
autoimmune thyroid disease, particularly Hashimoto’s
thryoiditis. In addition to the increased prevalence of
Hashimoto’s in patients with type I diabetes, there is a
marked increase of this thyroid disorder in the parents and
siblings of diabetic probands. In a large study [76,77], the
prevalence of Hashimoto’s thyroiditis was 16.2 and 25.3%
in male and female siblings under the age of 40 years,
respectively. This suggests a lS of at least 20 for Hashimo-
to’s thyroiditis in families with a type I diabetic proband.
The clinical association of RA with autoimmune thyroid
disease is well known, but there has been little formal
investigation of familial aggregation of these two disor-
ders. A recent small study of families of RA probands [78]
revealed an increase in both autoimmune thyroid disease
and type I diabetes in the first-degree relatives. Families
of patients with inflammatory myopathy also exhibit
familial aggregation of RA, thyroid disease, and type I dia-
betes [79]. Thus, although the data is still relatively
sparse, it appears likely that RA, type I diabetes, and
autoimmune thyroid disease actually do aggregate in fami-
lies [80], and this presumably reflects the effects of
common genes for these disorders. Whether this aggrega-
tion of autoimmune diseases extends to other less
common disorders such as multiple sclerosis and lupus is
unclear. Convincing epidemiological data on large popula-
tions are not currently available. 
In September 1999, the National Institute of Immunology,
Allergy, and Infectious Diseases awarded a major contract
to gather a large number of families in which multiple
autoimmune disorders aggregate together. (For more infor-
mation, readers may contact the author at peterg@nshs.edu,
Dr Timothy Behrens at behre001@maroon.tc.umn.edu, or
Dr Lindsey Criswell at lac@itsa.ucsf.edu). This database
and repository will include multiplex families with RA as
well as a number of other autoimmune diseases such as
lupus, type I diabetes, multiple sclerosis, and autoimmune
thryoid disease. Similar to the major collections of RA fami-
lies, this new family collection will provide additional
resources for individual researchers to investigate the
genetic relationships between various forms of autoimmu-
nity.
Conclusion
This brief review emphasizes the need for major collabo-
rative efforts between clinicians, immunologists, geneti-
cists, and statisticians in order to tease apart the complex
genetic factors that underlie RA and other forms of
autoimmunity. The completion of the Human Genome
Project is going to accelerate and complicate the process of
gene discovery. In his recent book, The Sun, the Genome,
and the Internet, Dyson [81] has articulated the importance
of new tools, as well as new ideas, for the craft of doing
science. It is increasingly apparent that both the genome
and the Internet are new tools that will have a major
impact on chasing down the genetic basis of rheumatoid
arthritis.
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